8-K: Denali Therapeutics Reports Q2 2024 Results, Regains Rights to Alzheimer's Program

Denali Therapeutics announced its second quarter 2024 financial results, highlighted by the regaining of rights to its ATV:Abeta Alzheimer's program and progress in its clinical pipeline.

Summary

• Denali Therapeutics reported a net loss of $99.0 million for the second quarter of 2024, compared to a net income of $183.4 million for the same period in 2023.
• The company experienced a significant decrease in collaboration revenue, from $294.1 million in Q2 2023 to zero in Q2 2024, primarily due to the absence of a large licensing payment from Biogen.
• Research and development expenses decreased slightly to $91.4 million, down from $97.5 million in the prior year, due to the divestiture of preclinical small molecule programs and the discontinuation of certain clinical programs.
• Denali regained full rights to its ATV:Abeta program for Alzheimer's disease from Biogen, expanding its opportunities in this area.
• The company's cash, cash equivalents, and marketable securities totaled approximately $1.35 billion as of June 30, 2024.
• Denali is advancing multiple clinical programs, including tividenofusp alfa (DNL310) for MPS II, DNL343 for ALS, and DNL126 for MPS IIIA, with several milestones expected in the second half of 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments such as regaining the ATV:Abeta program and progress in clinical trials, the significant decrease in revenue and net loss for the quarter temper the overall outlook. The company's strong cash position provides some reassurance.

Positives

• Denali regained full rights to the ATV:Abeta program, providing an opportunity to develop a potential best-in-class treatment for Alzheimer's disease.
• The FDA is open to discussing an accelerated approval pathway for tividenofusp alfa (DNL310) in MPS II, using cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate biomarker.
• DNL126 was selected for the FDA's START program, which should facilitate and accelerate its development.
• The company has a strong cash position of $1.35 billion, providing financial stability for ongoing research and development.
• Denali is advancing multiple clinical programs across various neurodegenerative and lysosomal storage diseases.

Negatives

• The company reported a net loss of $99.0 million for the quarter, a significant decrease from the net income of $183.4 million in the same quarter of the previous year.
• Collaboration revenue decreased to zero for the quarter, down from $294.1 million in the same quarter of the previous year.
• Research and development expenses, while decreased, still represent a significant cost at $91.4 million for the quarter.
• The discontinuation of clinical development of TAK-920/DNL919 (ATV:TREM2) and the voluntary pause of Part B in the TAK-594/DNL593 (PTV:PGRN) Phase 1/2 study are setbacks.

Risks

• The company faces risks related to the development and commercialization of its product candidates, including clinical trial outcomes and regulatory approvals.
• There is a risk of potential termination of collaboration agreements with partners like Sanofi, Takeda, or Biogen.
• The company is dependent on the successful development of its blood-brain barrier platform technology.
• There are risks associated with the company's ability to enroll patients in clinical trials and the potential for adverse events or toxicities.
• The company's ability to obtain additional capital to finance its operations is a risk.

Future Outlook

Denali expects to provide an update on the accelerated approval pathway for tividenofusp alfa in the second half of 2024 and anticipates several milestones across its clinical programs in the coming months. The company also plans to advance its ATV:Abeta program and continue to develop its technology platforms.

Management Comments

• Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics, stated that the Enzyme Transport Vehicle franchise gained additional momentum with continued engagement with the FDA on an accelerated approval pathway for tividenofusp alfa (DNL310) in MPS II.
• Ryan Watts also mentioned the FDA's selection of DNL126 (ETV:SGSH) in MPS IIIA for the START program.
• Ryan Watts expressed pleasure in regaining the rights to the TfR-based ATV:Abeta program from Biogen, expanding opportunities for addressing Alzheimer's disease.

Industry Context

The announcement reflects the ongoing focus on developing treatments for neurodegenerative and lysosomal storage diseases, with a particular emphasis on therapies that can cross the blood-brain barrier. The regaining of the ATV:Abeta program highlights the competitive landscape in Alzheimer's disease research and the importance of innovative delivery technologies. The FDA's START program selection of DNL126 underscores the regulatory support for rare disease therapeutics.

Comparison to Industry Standards

• Denali's focus on blood-brain barrier crossing technologies aligns with a key challenge in developing effective treatments for neurological disorders, similar to companies like Biohaven and Cerevel Therapeutics.
• The development of enzyme replacement therapies for lysosomal storage diseases, such as Denali's tividenofusp alfa, is comparable to efforts by companies like BioMarin and Sanofi Genzyme.
• The pursuit of accelerated approval pathways, as seen with Denali's DNL310, is a common strategy in the rare disease space, mirroring approaches taken by companies like Sarepta Therapeutics.
• The return of the ATV:Abeta program to Denali is a unique situation, as most Alzheimer's programs are developed in collaboration with large pharmaceutical companies, such as Biogen's collaboration with Eisai on lecanemab.
• Denali's cash position of $1.35 billion is relatively strong compared to many other biotech companies of similar size, providing a solid foundation for continued development.

Related Party Transactions

• The document mentions related-party collaboration revenue from customers of $294.1 million and $294.3 million for the three and six months ended June 30, 2023, respectively.
• The document also mentions expenses for cost sharing payments due to a related party of $7.0 million and $11.1 million for the three and six months ended June 30, 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decrease in revenue, but encouraged by the progress in clinical trials and the regaining of the ATV:Abeta program.
• Employees may be affected by the decrease in personnel-related expenses, but the company's strong cash position provides some stability.
• Patients with neurodegenerative and lysosomal storage diseases may benefit from the company's ongoing research and development efforts.
• Collaborators and partners may be impacted by the changes in collaboration agreements and program development.

Next Steps

• Denali will continue engagement with the FDA regarding the accelerated approval pathway for tividenofusp alfa.
• The company will provide an update on the accelerated approval pathway for tividenofusp alfa in the second half of 2024.
• Denali plans to initiate a global Phase 2a study in 2024 to evaluate safety and biomarkers associated with BIIB122 in participants with Parkinsons disease and confirmed pathogenic variants of LRRK2.
• Phase 1/2 biomarker and safety data for DNL126 are expected by the end of 2024.
• Denali plans to advance a TfR-targeting ATV:Abeta molecule as well as a CD98hc-targeting ATV:Abeta molecule into development for Alzheimer's disease.
• Denali will participate in several upcoming investor conferences.

Key Dates

Keywords

Denali Therapeutics, Neurodegenerative Diseases, Lysosomal Storage Diseases, Blood-Brain Barrier, Alzheimer's Disease, Parkinson's Disease, MPS II, MPS IIIA, Clinical Trials, Biotechnology, Tividenofusp alfa, DNL310, DNL126, ATV:Abeta, ETV, FDA, START Program